Hørsholm, Denmark

Mads Aaboe Jensen

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 8.0

ph-index = 3

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Mads Aaboe Jensen: Innovator in Oligonucleotide Technology

Introduction

Mads Aaboe Jensen is a distinguished inventor based in Hørsholm, Denmark. He has made significant contributions to the field of biotechnology, particularly in the development of oligonucleotides for therapeutic applications. With a total of six patents to his name, Jensen's work focuses on innovative solutions for genetic disorders.

Latest Patents

One of Jensen's notable patents is related to oligonucleotides that induce paternal UBE3A expression. This invention aims to enhance the expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in neurons. The oligonucleotides specifically target the suppressor of the UBE3A paternal allele by hybridizing to SNHG14 long non-coding RNA downstream of SNORD1091B. This groundbreaking work also includes pharmaceutical compositions and methods for treating Angelman syndrome, a genetic disorder that affects the nervous system.

Career Highlights

Throughout his career, Mads Aaboe Jensen has worked with prominent companies in the biotechnology sector. He has been associated with Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. His experience in these organizations has allowed him to contribute to cutting-edge research and development in the field.

Collaborations

Jensen has collaborated with several professionals in his field, including Veronica Costa and Maj Hedtjärn. These partnerships have facilitated the advancement of his research and the successful development of his patented technologies.

Conclusion

Mads Aaboe Jensen is a notable inventor whose work in oligonucleotide technology has the potential to transform treatments for genetic disorders. His innovative patents and collaborations highlight his commitment to advancing biotechnology for therapeutic purposes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…